Business
Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting
VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical‑stage biopharmaceutical company developing multifunctional
About this update from Zymeworks Inc.
[{"type":"text","content":" VANCOUVER, British Columbia--(BUSINESS WIRE)--\nZymeworks Inc. (NYSE: ZYME), a clinical‑stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General Meeting of Shareholders held on May 5, 2021 (the “Meeting”).\n\nShareholder Voting Results\n\nThe Shareholders voted on the following matters at this year’s Meeting.\n\nProposal 1 – Election of Directors\n\nThe nominees listed in Zymeworks’ proxy statement dated March 23, 2021 (the “Proxy Statement”) were elected as Directors of the Company. Detailed results of the votes are set out below:\n\n\n\nProposal 1\n\n\n\nOutcome of the Vote\n\n\n\nVotes by Ballot\n\n\n\n\n\nElection of Directors\n\n\n\nVotes For\n\n\n\nVotes Withheld\n\n\n\n\n\nSusan Mahony\n\n\n\nCarried\n\n\n\n19,286,855\n(71.48%)\n\n\n\n7,695,418\n(28.52%)\n\n\n\n\n\nKelvin Neu\n\n\n\nCarried\n\n\n\n19,377,998\n(71.82%)\n\n\n\n7,604,275\n(28.18%)\n\n\n\n\n\nAli Tehrani\n\n\n\nCarried\n\n\n\n19,375,651\n(71.81%)\n\n\n\n7,606,622\n(28.19%)\n\n\n\n\nProposal 2 – Advisory Vote on Executive Compensation\n\nThe Shareholders approved, on an advisory basis, the compensation of the Company’s named executive officers. Detailed results of the votes are set out below:\n\n\n\nProposal 2\n\n\n\nOutcome of the Vote\n\n\n\nVotes by Ballot\n\n\n\n\n\n \n\n\n\nVotes For\n\n\n\nVotes Against\n\n\n\nVotes Abstaining\n\n\n\n\n\nAdvisory Vote on Executive Compensation\n\n\n\nCarried\n\n\n\n24,095,093\n(89.30%)\n\n\n\n2,607,651\n(9.66%)\n\n\n\n279,529\n(1.04%)\n\n\n\n\nProposal 3 – Appointment of Auditors\n\nThe vote was carried for the appointment of the Auditors, KPMG LLP. Detailed results of the votes are set out below:\n\n\n\nProposal 3\n\n\n\nOutcome of the Vote\n\n\n\nVotes by Ballot\n\n\n\n\n\n \n\n\n\nVotes For\n\n\n\nVotes Withheld\n\n\n\n\n\nAppointment of KPMG LLP\n\n\n\nCarried\n\n\n\n28,930,162\n(98.99%)\n\n\n\n296,499\n(1.01%)\n\n\n\n\nFull details of all proposals are fully described in the Proxy Statement available on the Company’s profile on SEDAR at www.sedar.com, and on EDGAR at www.sec.gov, and the detailed results of voting on each proposal are included in the Report of Voting Results filed on SEDAR and on EDGAR.\n\nAbout Zymeworks Inc.\n\nZymeworks is a clinical-stage biopharmaceutical company dedi...